NSEAnalysts/Institutional Investor Meet/Con. Call Updates▲ PositiveResults20 Aug 2026
Zota Health Care LImited
Analysts/Institutional Investor Meet/Con. Call Updates
Zota Health Care Limited has informed the Exchange about the Transcript of Earnings Conference Call on financial results for the quarter ended June 30, 2026. The company has delivered robust growth across its operations, supported by a sustained expansion of the Davaindia Network and increasing consumer acceptance of affordable healthcare solutions. The company has added 264 new Davaindia stores, taking its total store strength to 2,825 stores across the country as of June 30, 2026. The company has also increased its investment in Davaindia Health Mart Limited through a right issue, further reinforcing its commitment towards scaling India's largest organized private-label pharmacy platform.
NSECopy of Newspaper PublicationResults15 Aug 2026
Zota Health Care LImited
Copy of Newspaper Publication
Zota Health Care Limited has published newspaper advertisements for its unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
NSEAnalysts/Institutional Investor Meet/Con. Call UpdatesResults14 Aug 2026
Zota Health Care LImited
Analysts/Institutional Investor Meet/Con. Call Updates
Zota Health Care Limited has informed the Exchange about the availability of the audio recording link of its earnings conference call on financial results for the quarter ended June 30, 2026.
NSEMonitoring Agency ReportResults14 Aug 2026
Zota Health Care LImited
Monitoring Agency Report
Zota Health Care Limited has received a Monitoring Agency Report from CRISIL Ratings Limited for the utilization of funds raised through Qualified Institutional Placement for the quarter ended June 30, 2026. The report has been reviewed by the Audit committee and Board of Directors of the Company.
NSEInvestor PresentationResults13 Aug 2026
Zota Health Care LImited
Investor Presentation
Zota Health Care Limited has submitted an investor presentation for Q1FY27, highlighting its business overview, financial highlights, and growth prospects.
NSEStatement of deviation(s) or variation(s) under Reg. 32Results13 Aug 2026
Zota Health Care LImited
Statement of deviation(s) or variation(s) under Reg. 32
Zota Health Care Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, stating that there is no deviation or variation in the utilization of Qualified Institutional Placement proceeds for the quarter ended June 30, 2026.
NSEPress Release▲ PositiveResults13 Aug 2026
Zota Health Care LImited
Press Release
Zota Health Care Limited has announced its Q1FY27 financial results, with consolidated revenues growing by 67.59% YoY to ₹17,360.23 lakhs, driven by network expansion and healthy demand across existing stores. The company added 264 new stores during Q1FY27 and appointed Mr. Akshay Kumar as the Brand Ambassador for Zota Health Care and UGO Generic.
NSEOutcome of Board MeetingResults13 Aug 2026
Zota Health Care LImited
Outcome of Board Meeting
Zota Health Care Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results and the auditor issuing a review report with an unmodified review conclusion.
NSEAnalysts/Institutional Investor Meet/Con. Call UpdatesResults6 Aug 2026
Zota Health Care LImited
Analysts/Institutional Investor Meet/Con. Call Updates
Zota Health Care Limited has informed the Exchange about Intimation of Schedule of Earnings Conference Call on Q1FY27 Results.
NSECopy of Newspaper PublicationRegulatory25 Jul 2026
Zota Health Care LImited
Copy of Newspaper Publication
Zota Health Care Limited has informed the Exchange about the transfer of equity shares to the Investor Education and Protection Fund (IEPF) Account, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
NSEGeneral UpdatesDebt Restruc.24 Jul 2026
Zota Health Care LImited
General Updates
Zota Health Care Limited has informed the Exchange about communication to the Shareholders regarding compulsory transfer of unclaimed/unpaid dividend/shares of financial year 2018-19 to the Investor Education and Protection Fund.
NSECorrigendumResults23 Jul 2026
Zota Health Care LImited
Corrigendum
Zota Health Care Limited has issued a corrigendum to its consolidated cash flow statement for the year ended March 31, 2026, correcting inadvertent typographical errors.
NSEAcquisitionM&A17 Jul 2026
Zota Health Care LImited
Acquisition
Zota Health Care Limited has acquired 2,35,512 equity shares of its wholly-owned subsidiary Davaindia Health Mart Limited on a preferential basis for consideration other than cash, reducing the company's total outstanding debt and improving its net worth.
NSECertificate under SEBI (Depositories and Participants) Regulations, 201815 Jul 2026
Zota Health Care LImited
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Zota Health Care Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
NSEGeneral Updates▲ PositiveExpansion1 Jul 2026
Zota Health Care LImited
General Updates
Zota Health Care Limited has informed the Exchange about Davaindia Stores Update for Q1FY27, with the company opening 264 new Davaindia stores during the period.
NSETrading Window26 Jun 2026
Zota Health Care LImited
Trading Window
Zota Health Care Limited has informed the Exchange regarding the closure of the trading window for its promoters, directors, key managerial personnel, designated employees, and their immediate relatives from July 1, 2026, until 48 hours after the announcement of the unaudited financial results for the quarter ended June 30, 2026.
NSEAcquisitionM&A22 Jun 2026
Zota Health Care LImited
Acquisition
Zota Health Care Limited has acquired an 80% stake in Globotask IT Consultancy Services Private Limited (GITCPL) for a cash consideration of INR 25 lakhs. GITCPL, an IT software and services company, generated a turnover of INR 19.28 lakhs in FY 2025-26. The acquisition aims to provide IT solutions, including cloud-based software, app development, and ERP, to Zota Health Care and its subsidiaries, making GITCPL a subsidiary.
NSEAcquisition▲ PositiveExpansion22 Jun 2026
Zota Health Care LImited
Acquisition
Zota Health Care Limited has acquired 20,00,000 equity shares of its wholly-owned subsidiary, KMHP Ventures Limited, by subscribing to a rights issue for Rs. 2 crore. KMHP Ventures, a pharmaceutical company with NIL turnover in FY26, plans to launch a PAN India retail store chain called "Ugo Generic" for B2B and B2C sales of generic medicines. This strategic investment aims to support KMHP's expansion into the generic retail segment, onboarding ~12.5 lakh retail pharmacies.
NSEAcquisition▲ PositiveM&A22 Jun 2026
Zota Health Care LImited
Acquisition
Zota Health Care Limited has acquired 1,000,000 equity shares of its wholly-owned subsidiary, Curexis Ventures Private Limited, for Rs. 2 crore through a rights issue subscription. This strategic investment aims to expand Curexis's SKIA retail pharmacy stores and address its working capital needs. Curexis, engaged in drug manufacturing, development, and marketing, will continue as a wholly-owned subsidiary post-acquisition. The subsidiary reported a turnover of Rs. 1.18 lakhs in FY2025-26. The transaction was a cash consideration.
NSETrading Window19 Jun 2026
Zota Health Care LImited
Trading Window
Zota Health Care Limited has signed a Memorandum of Understanding (MOU) to acquire an 80% stake in M/s Globotask IT Consultancy Services Private Limited (GITCL). The company will acquire 8,000 equity shares of GITCL for an aggregate consideration of Rs. 25,00,000/- (Twenty-Five Lakhs Only). This strategic move signifies Zota Health Care's potential diversification or expansion into IT consultancy services. Following this significant announcement, the trading window for the company's shares has been closed to prevent insider trading.